CPHI China 2026 | Value Co-created, Future Shared

Shanghai, China, June 2026 – The 24th World Pharmaceutical Ingredients China (CPHI China 2026) grandly opened at the Shanghai New International Expo Center. Covering an exhibition area of 250,000 square meters, the event brought together over 3,700 exhibitors and 110,000 professional visitors from around the world – a truly unprecedented scale. This is more than just an industry event; it marks a new starting point for the global pharmaceutical community to join hands and explore the future together.

Lianhe Aigen, with years of deep expertise in the pharmaceutical CRDMO sector, firmly believes that trust is built on strength and success is forged through collaboration. Our participation in this exhibition was not only a comprehensive showcase of our one-stop CRDMO capabilities, but also a pivotal opportunity to strengthen partnerships and pursue shared growth with our global clients.

Throughout CPHI 2026, our team engaged in in-depth discussions with dozens of clients and partners from Europe, North America, Asia, and beyond. Through these face-to-face interactions, we keenly sensed that for prospective clients, the foremost question is always: Can Lianhe Aigen be truly trusted in terms of technology, capacity, quality, and service? For our established partners, however, the conversation has moved beyond "can it be done" to "how can we go further together."

To both new and existing partners, we respond with the same sincerity and professionalism. In terms of technological capabilities, we cover a broad spectrum including small molecules, oligonucleotides, peptides, and ADCs, with an end-to-end platform from R&D to commercialization. In terms of capacity, we have built a tiered production system scaling from grams to metric tons, ensuring seamless project progression. In terms of quality, we have passed inspections and obtained certifications from multiple authoritative agencies including FDA, EMA, NMPA, PMDA, TGA and MFDS, safeguarding our global clients with internationally recognized standards. In terms of service, we remain committed to a client-centric approach, delivering tailored end-to-end solutions from early-stage development through to commercial supply.

The path to pharmaceutical innovation is never straightforward. Process development poses constant challenges, and the road to commercialization is filled with both obstacles and opportunities. It is precisely for this reason that Lianhe Aigen chooses to stand firmly alongside our clients – leveraging our solid technology, reliable capacity, uncompromising quality, and dedicated service to build the strongest possible foundation for every innovative drug program.

Our Mission has always been clear and unwavering: Empower Global Innovative Medicines and Contribute to Human Health.

CPHI China 2026 was a wonderful gathering, and more importantly, it marks the beginning of lasting collaborations. We look forward to transforming the consensus reached at the exhibition into tangible cooperation outcomes. Together with our global partners, we aim to achieve mutual success, support one another throughout the journey of innovative drug development, and collectively advance toward a brighter future for human health.

Lianhe Aigen – Trusted Partner. Value Co-created. Future Shared.